~~<i id='3E407C52C9'><strike id='3E407C52C9'><tt id='3E407C52C9'><pre id='3E407C52C9'></pre></tt></strike></i>~~

Home» leisure time» explore

explore

author：fashion 2025-09-28 05:46:29 Page View：75

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： More doctors should go into startup world
Next article： Sports medicine is finally prioritizing gender equality

explore

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

MoonLake credibility takes another hit with mid

MollyFerguson/STATMoonLakeImmunotherapeutics,aSwissbiotech,wasburiedMondayunderanavalancheofitsownda

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

FDA approves potent Eli Lilly obesity drug, Zepbound

DarronCummings/APEliLilly’sblockbusterdrugtirzepatide,soldasMounjarofortype2diabetes,hasbeenclearedt